What is the projected market valuation of the Brucellosis Vaccine Market by 2035?

The Brucellosis Vaccine Market is projected to reach a valuation of 2.498 USD Billion by 2035. Read More

What was the market valuation of the Brucellosis Vaccine Market in 2024?

In 2024, the Brucellosis Vaccine Market was valued at 1.594 USD Billion. Read More

What is the expected CAGR for the Brucellosis Vaccine Market during the forecast period 2025 - 2035?

The expected CAGR for the Brucellosis Vaccine Market during the forecast period 2025 - 2035 is 4.17%. Read More

Which companies are considered key players in the Brucellosis Vaccine Market?

Key players in the Brucellosis Vaccine Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and others. Read More

What are the different types of vaccines available in the Brucellosis Vaccine Market?

The Brucellosis Vaccine Market includes Live Attenuated, Inactivated, Recombinant, and Subunit vaccines. Read More

How did the valuation of Live Attenuated Vaccines change from 2024 to 2025?

The valuation of Live Attenuated Vaccines increased from 0.637 USD Billion in 2024 to 0.999 USD Billion in 2025. Read More

What is the market size for cattle in the Brucellosis Vaccine Market?

The market size for cattle in the Brucellosis Vaccine Market was 0.797 USD Billion in 2024 and is expected to reach 0.999 USD Billion in 2025. Read More

What administration routes are utilized for Brucellosis vaccines?

Brucellosis vaccines are administered via Subcutaneous, Intramuscular, and Oral routes. Read More

What is the expected market performance for veterinary clinics in the Brucellosis Vaccine Market?

Veterinary clinics are projected to grow from 0.637 USD Billion in 2024 to 0.999 USD Billion in 2025. Read More

How does the market for goats compare to that for cattle in the Brucellosis Vaccine Market?

The market for goats was valued at 0.398 USD Billion in 2024, significantly lower than the cattle market, which was 0.797 USD Billion. Read More

Brucellosis Vaccine Market

Global Brucellosis Vaccine Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Subunit Vaccines), By Animal Type (Cattle, Goats, Sheep, Dogs), By Administration Route (Subcutaneous, Intramuscular, Oral), By End Use (Veterinary Clinics, Research Institutions, Animal Farms) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.17%

2024 Market Size

$ 1.59 Billion

2035 Market Size

$ 2.5 Billion

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/41551-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Vaccine Type (USD Billion)
  1. 4.1.1 Live Attenuated Vaccines
  2. 4.1.2 Inactivated Vaccines
  3. 4.1.3 Recombinant Vaccines
  4. 4.1.4 Subunit Vaccines
2. 4.2 Healthcare, BY Animal Type (USD Billion)
  1. 4.2.1 Cattle
  2. 4.2.2 Goats
  3. 4.2.3 Sheep
  4. 4.2.4 Dogs
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Subcutaneous
  2. 4.3.2 Intramuscular
  3. 4.3.3 Oral
4. 4.4 Healthcare, BY End Use (USD Billion)
  1. 4.4.1 Veterinary Clinics
  2. 4.4.2 Research Institutions
  3. 4.4.3 Animal Farms
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Intervet (NL)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vetoquinol (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Heska Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ceva Santé Animale (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Virbac (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY VACCINE TYPE
4. 6.4 US MARKET ANALYSIS BY ANIMAL TYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 US MARKET ANALYSIS BY END USE
7. 6.7 CANADA MARKET ANALYSIS BY VACCINE TYPE
8. 6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE
9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY END USE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY VACCINE TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY END USE
16. 6.16 UK MARKET ANALYSIS BY VACCINE TYPE
17. 6.17 UK MARKET ANALYSIS BY ANIMAL TYPE
18. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
19. 6.19 UK MARKET ANALYSIS BY END USE
20. 6.20 FRANCE MARKET ANALYSIS BY VACCINE TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY END USE
24. 6.24 RUSSIA MARKET ANALYSIS BY VACCINE TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY END USE
28. 6.28 ITALY MARKET ANALYSIS BY VACCINE TYPE
29. 6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE
30. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY END USE
32. 6.32 SPAIN MARKET ANALYSIS BY VACCINE TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY END USE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY VACCINE TYPE
42. 6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE
43. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY END USE
45. 6.45 INDIA MARKET ANALYSIS BY VACCINE TYPE
46. 6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE
47. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY END USE
49. 6.49 JAPAN MARKET ANALYSIS BY VACCINE TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY END USE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
57. 6.57 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USE
61. 6.61 THAILAND MARKET ANALYSIS BY VACCINE TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY END USE
65. 6.65 INDONESIA MARKET ANALYSIS BY VACCINE TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY END USE
69. 6.69 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY VACCINE TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY END USE
78. 6.78 MEXICO MARKET ANALYSIS BY VACCINE TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY END USE
82. 6.82 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
99. 6.99 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY VACCINE TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Brucellosis Vaccine Market Segmentation

Brucellosis Vaccine Market By Vaccine Type (USD Billion, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Subunit Vaccines

Brucellosis Vaccine Market By Animal Type (USD Billion, 2025-2035)

Cattle
Goats
Sheep
Dogs

Brucellosis Vaccine Market By Administration Route (USD Billion, 2025-2035)

Subcutaneous
Intramuscular
Oral

Brucellosis Vaccine Market By End Use (USD Billion, 2025-2035)

Veterinary Clinics
Research Institutions
Animal Farms

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”